Director Mineo Chrysa buys 3,320 shares at blended avg $22.26 in 2-transaction filing at loss-making biotech.
Mineo Chrysa, a Director at Cidara Therapeutics, made 2 separate purchases totaling 3,320 shares for $73,895.57, acquired at $21.71 on 2025-06-02 and $23.44 on 2025-06-03. This represents a new position; Chrysa held zero shares prior to these transactions. The purchases occurred while CDTX stock was near its 52-week high of $27.30 and has since appreciated 11.9% in the 30-day period following the transaction window, trading at $24.05 currently (down 11.9% from the 52-week high). Cidara's fundamentals remain challenged: the company reported $0.00 revenue in the latest quarter, a net loss of $-23,480,000.00, and annual revenue contraction of -98.0%, reflecting an unprofitable biotech in a critical phase. A director's initial equity stake purchase warrants baseline disclosure attention, though the absence of prior holdings history and the company's severe loss position limit the interpretive signal.